![Jeanette Leusen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Jeanette Leusen
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
TigaTx BV
![]() TigaTx BV Miscellaneous Commercial ServicesCommercial Services TigaTx BV is a Dutch company that provides research and development in the field of health nutrition. The company is based in Utrecht, the Netherlands. The company was founded in 2020 by Jeanette Leusen.
2
| Holding Company | Miscellaneous Commercial Services | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jeanette Leusen
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Biogeneration Management BV
![]() Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Investment Managers | President | |
Genase Therapeutics BV
![]() Genase Therapeutics BV Pharmaceuticals: MajorHealth Technology Genase Therapeutics BV develops therapeutic products to treat solid tumors. The company is based in Oss, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Venatorx Pharmaceuticals, Inc.
![]() Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Miscellaneous Commercial Services | Director/Board Member | |
Rgenta Therapeutics, Inc.
![]() Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Rgenta Therapeutics, Inc. manufactures medicines for oncology and neurological disorders. The company was founded by Simon Xi, Travis Wager, and Zhiping Weng and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Abexxa Biologics, Inc.
![]() Abexxa Biologics, Inc. Pharmaceuticals: MajorHealth Technology AbeXXa Biologics, Inc. is engaged in biopharmaceutical services. The company was founded by Jon Weidanz and Debra Weidanz in 2015 and is headquartered in Arlington, TX. | Pharmaceuticals: Major | Director/Board Member | |
Tilos Therapeutics, Inc.
![]() Tilos Therapeutics, Inc. BiotechnologyHealth Technology Tilos Therapeutics, Inc. designs and develops biotechnology products such as developing new treatments for cancer, fibrosis and autoimmune disease. It develops antibody therapeutics that target key immunological pathways, with a primary focus on regulatory T cells and regulation of effector cells. The company was founded by Howard L. Weiner in 2016 and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
Sentien Biotechnologies, Inc.
![]() Sentien Biotechnologies, Inc. BiotechnologyHealth Technology Sentien Biotechnologies, Inc. develops cell-based therapy for critical care. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions. The company was founded by Brian Miller and Biju Parekkadan and is headquartered in Lexington, MA. | Biotechnology | Director/Board Member | |
ArmaGen, Inc.
![]() ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
![]() Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
TigaTx, Inc.
![]() TigaTx, Inc. BiotechnologyHealth Technology TigaTx, Inc. is a biotechnology company that focuses on developing first-in-class, engineered IGA as neutrophil engagers to fight cancer. The company is based in Boston, MA. TigaTx is backed by excellent investors and has an accomplished scientific advisory board. It was founded by Jeanette Leusen and the CEO is Anne Altmeyer. | Biotechnology | Director/Board Member | |
Scenic Biotech BV
![]() Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
Dualyx NV
![]() Dualyx NV Miscellaneous Commercial ServicesCommercial Services Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven. | Miscellaneous Commercial Services | Director/Board Member | |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Escalier Biosciences BV
![]() Escalier Biosciences BV BiotechnologyHealth Technology Escalier Biosciences BV develops biological products. The company is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member | |
SynAffix BV
![]() SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Biotechnology | Director/Board Member | |
Cristal Delivery BV
![]() Cristal Delivery BV Pharmaceuticals: MajorHealth Technology Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Stichting Publieke Private Samenwerking Versterking
![]() Stichting Publieke Private Samenwerking Versterking Investment Trusts/Mutual FundsMiscellaneous Stichting Mibiton promotes research, development, and entrepreneurship in the life sciences sector. The foundation is focused on biomedical sciences, chemistry, food, agricultural, and environmental technology. Stichting Mibiton was founded in 1994, formally called as Stichting Publieke Private Samenwerking Versterking van de Materiële Infrastructuur BioTechnologisch Onderzoek in Nederland and is based in The Hague, The Netherlands. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Delft University of Technology | College/University | Graduate Degree | |
University of Utrecht | College/University | Graduate Degree | |
Polpharma Biologics Utrecht BV
![]() Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Director/Board Member | |
Janssen Pharmaceuticals, Inc.
![]() Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Vedanta Biosciences, Inc.
![]() Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member |
Statistik
International
Niederlande | 15 |
Vereinigte Staaten | 12 |
Belgien | 3 |
Sektoral
Health Technology | 16 |
Commercial Services | 5 |
Finance | 3 |
Health Services | 3 |
Consumer Services | 3 |
Operativ
Director/Board Member | 21 |
Corporate Officer/Principal | 3 |
Private Equity Investor | 2 |
Graduate Degree | 2 |
President | 1 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Edward van Wezel | 20 |
Martin Heidecker | 9 |
- Börse
- Insiders
- Jeanette Leusen
- Unternehmensverbindungen